New Human Chimeric Monoclonal Antibodies: PL-7 humAb IgG, PL-12 humAb IgG and Sp100 humAb IgG -- MEDICA - World Forum for Medicine

11/08/2018

DIARECT AG

New Human Chimeric Monoclonal Antibodies: PL-7 humAb IgG, PL-12 humAb IgG and Sp100 humAb IgG

For mRNA translation at the ribosomes, amino acids are covalently attached (“loaded”) onto their respective tRNAs by specific aminoacyl-tRNA synthetases. Threonyl-tRNA synthetase (PL-7) is specific for the amino acid threonine and Alanyl-tRNA synthetase (PL-12) is specific for the amino acid alanine.

PL-7 and PL-12 autoantibodies are considered important serological markers in dermatomyositis, an idiopathic myopathy characterized by the presence of inflammatory infiltrates within skeletal muscle. Together with polymyositis, dermatomyositis is one of the most common subtypes of these idiopathic myopathies along with inclusion body myositis, childhood myositis, malignancy-associated myositis, and myositis in overlap with mixed connective tissue disease. To date, autoantibodies targeting eight of the 20 aminoacyl-tRNA synthetases have been identified, being found in up to 30% of sera from patients with myositis. They are highly specific for this disorder and strongly associated with complicating lung disease.

Sp100 is a nuclear protein with a deduced molecular weight of 55 kDa that is named after its speckled/multinuclear dots pattern (MND-ANA) in IIF and aberrant mobility at 100 kDa in protein gels. The cellular function of Sp100 is not well understood, but it appears to be involved in the regulation of gene transcription and the cellular response to viral infections. Primary Biliary Cirrhosis (PBC) is a chronic and progressive autoimmune liver disease, which is characterized by the destruction of bile ducts and portal inflammation leading to liver cirrhosis and consequently to hepatic failure. Autoantibodies are directed against Sp100, found in approximately 25% of PBC patients and are considered a highly specific marker in the diagnosis of this disease.

Technological breakthroughs and innovative technologies continue to shape the in vitro diagnostic field. One of these advances in assay development are chimeric monoclonal antibodies for use as positive controls or calibrators in IVD kits as an alternative to characterized disease state plasma, which are limited in availability, show variability, and have safety and ethical issues.

These chimeric monoclonal antibodies are produced in transgenic mouse strains in which the sequence for mouse IgG1 Fc region is substituted with the human sequence. After mouse immunization and hybridoma technology, antibodies are generated that retain a human constant region required for recognition by the anti-human conjugate. These monoclonal antibodies can then be produced using standard cell culture technologies.

DIARECT has been continually expanding the line of tissue-specific chimeric antibodies for the detection and diagnosis of autoimmune liver diseases, and with these new products, we have completed our portfolio of myositis antibodies.

References:
Betteridge et al. (2011) Arthritis Research & Therapy. 13:209-215
Cogné et al. (2013) European Patent N°13305964.2
Gunawardena et al. (2015) Clinic Rev Allerg Immunol. DOI 10.1007/s12016-015-8513-8
Invernizzi et al. (2008) World J Gastroenterol. 21:3374-3387
Mathews et al. (1984) J Exp Med. 160:420-434
Oertelt et al. (2007) Hepatology. 45 (3): 659-665
Yamasaki et al. (2006) Arthritis & Rheumatism. 54: 2004–2009
Zhang et al. (2014) Hepatology. 60: 1708–1716
Sherer et al. (2004) Semin Arthritis Rheum. 34:501-537

For questions or additional information please feel free to contact us at:
Tel: +49 761 47979-0
Email: info@diarect.com

Exhibitor Data Sheet